Publication Venue For
Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.
The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer.
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
DNA topoisomerase-targeting chemotherapeutics: what’s new?.
Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients.
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: Remission and lack of host toxicity.
Lack of in vivo cross-resistance with 4′-thio-ara-C against drug-resistant murine P388 and L1210 leukemias.
A phase i study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer.
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study..
A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer.
Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: Effect on chemotherapy toxicity and efficacy.
Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity.
Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: Novel targets for therapy.
Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
5-(Phenylthio)acyclouridine: A powerful enhancer of oral uridine bioavailability: Relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens.
Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.
Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
Preclinical antitumor activity of 4′-thio-β-D-arabinofuranosylcytosine (4′-thio-ara-C).
Enhancement of the bioavailability of oral uridine by coadministration of 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: Implications for uridine rescue regimens in chemotherapy.
Modulation of the pharmacokinetics of endogenous plasma uridine by 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: Implications for chemotherapy.
Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2', 3', 5'-tri-O-acetyluridine, a prodrug of uridine: Relevance to uridine rescue in chemotherapy.
Modulation of plasma uridine concentration by 5- (phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: Relevance to chemotherapy.
Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma.
Etoposide sensitivity of radioresistant human glioma cell lines.
Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion.
The significance of the sequence of administration of topotecan and etoposide.
Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy.
Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer.
Yeast Saccharomyces cerevisiae as a model system to study the cytotoxic activity of the antitumor drug camptothecin.
Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck.
2,4-Diamino-6-(bis-2-chloroethyl)aminomethyl pteridine - A new potent anticancer drug.